Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 8 | 2009 | 1826 | 0.720 |
Why?
|
| Breast Neoplasms, Male | 3 | 2009 | 18 | 0.630 |
Why?
|
| Lactoferrin | 3 | 2009 | 76 | 0.580 |
Why?
|
| Oncologists | 1 | 2017 | 32 | 0.520 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2017 | 729 | 0.470 |
Why?
|
| Immunotherapy | 2 | 2013 | 768 | 0.470 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2017 | 357 | 0.450 |
Why?
|
| Multiple Myeloma | 2 | 2015 | 177 | 0.440 |
Why?
|
| Thalidomide | 1 | 2013 | 36 | 0.400 |
Why?
|
| Prostatic Neoplasms | 7 | 2012 | 1419 | 0.370 |
Why?
|
| Neoplasms, Second Primary | 1 | 2013 | 142 | 0.360 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2013 | 105 | 0.350 |
Why?
|
| Cancer Vaccines | 1 | 2013 | 191 | 0.340 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 789 | 0.340 |
Why?
|
| Neoplasm Metastasis | 5 | 2009 | 713 | 0.330 |
Why?
|
| Genetic Testing | 1 | 2017 | 1106 | 0.330 |
Why?
|
| Kidney Neoplasms | 3 | 2009 | 421 | 0.330 |
Why?
|
| Lung Neoplasms | 3 | 2017 | 1545 | 0.320 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 393 | 0.320 |
Why?
|
| Peptides | 1 | 2013 | 708 | 0.300 |
Why?
|
| Leiomyosarcoma | 1 | 2009 | 22 | 0.300 |
Why?
|
| Neoplasms | 5 | 2018 | 3016 | 0.290 |
Why?
|
| Nephrectomy | 1 | 2009 | 158 | 0.280 |
Why?
|
| Androgens | 1 | 2009 | 247 | 0.260 |
Why?
|
| Prostate-Specific Antigen | 3 | 2008 | 224 | 0.240 |
Why?
|
| Registries | 1 | 2013 | 1634 | 0.240 |
Why?
|
| Membrane Proteins | 2 | 2013 | 1590 | 0.240 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2005 | 47 | 0.220 |
Why?
|
| Recombinant Proteins | 3 | 2008 | 1319 | 0.220 |
Why?
|
| Middle Aged | 20 | 2018 | 28601 | 0.210 |
Why?
|
| Sulfonamides | 1 | 2005 | 296 | 0.190 |
Why?
|
| Pyrazoles | 1 | 2005 | 349 | 0.180 |
Why?
|
| Adenocarcinoma | 2 | 2005 | 972 | 0.170 |
Why?
|
| Male | 25 | 2018 | 64957 | 0.170 |
Why?
|
| Cachexia | 2 | 2012 | 57 | 0.160 |
Why?
|
| Bone Neoplasms | 1 | 2005 | 475 | 0.160 |
Why?
|
| Aged | 12 | 2018 | 21025 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 3436 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2012 | 480 | 0.130 |
Why?
|
| Habenula | 1 | 2018 | 39 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2015 | 1336 | 0.120 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2009 | 223 | 0.120 |
Why?
|
| Neural Pathways | 1 | 2018 | 270 | 0.120 |
Why?
|
| Humans | 28 | 2018 | 131163 | 0.120 |
Why?
|
| Weight Loss | 2 | 2018 | 538 | 0.120 |
Why?
|
| Brain Mapping | 1 | 2018 | 384 | 0.120 |
Why?
|
| Administration, Oral | 2 | 2009 | 711 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2015 | 6797 | 0.110 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 1994 | 3 | 0.110 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 1994 | 33 | 0.100 |
Why?
|
| Fingers | 1 | 1994 | 62 | 0.100 |
Why?
|
| Testosterone | 2 | 2012 | 531 | 0.100 |
Why?
|
| Interleukin-5 | 1 | 1993 | 49 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2018 | 1445 | 0.100 |
Why?
|
| Boronic Acids | 2 | 2015 | 47 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2011 | 2065 | 0.100 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 71 | 0.100 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1994 | 124 | 0.100 |
Why?
|
| Pyrazines | 2 | 2015 | 81 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 108 | 0.090 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 109 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 3 | 2011 | 400 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2008 | 387 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1993 | 174 | 0.090 |
Why?
|
| Decision Making | 1 | 2017 | 726 | 0.090 |
Why?
|
| Genes, Suppressor | 1 | 2011 | 11 | 0.090 |
Why?
|
| HLA Antigens | 1 | 2013 | 221 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 354 | 0.090 |
Why?
|
| Splenosis | 1 | 2011 | 2 | 0.080 |
Why?
|
| Survivors | 1 | 2013 | 344 | 0.080 |
Why?
|
| Diagnosis, Differential | 3 | 2011 | 1882 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1071 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 252 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 335 | 0.080 |
Why?
|
| Female | 10 | 2018 | 70963 | 0.080 |
Why?
|
| Abdomen | 1 | 2011 | 126 | 0.080 |
Why?
|
| Anorexia | 1 | 2010 | 23 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 1410 | 0.080 |
Why?
|
| United States | 2 | 2017 | 12072 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 371 | 0.080 |
Why?
|
| BRCA2 Protein | 1 | 2009 | 55 | 0.070 |
Why?
|
| Adipokines | 1 | 2010 | 119 | 0.070 |
Why?
|
| Receptors, Androgen | 1 | 2012 | 408 | 0.070 |
Why?
|
| Skin Diseases | 1 | 1990 | 143 | 0.070 |
Why?
|
| Demography | 1 | 2009 | 237 | 0.070 |
Why?
|
| Histone Acetyltransferases | 1 | 2008 | 226 | 0.070 |
Why?
|
| Prognosis | 3 | 2009 | 4886 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 680 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 1990 | 307 | 0.060 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2008 | 160 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2011 | 713 | 0.060 |
Why?
|
| Caveolin 1 | 1 | 2006 | 51 | 0.060 |
Why?
|
| Incidence | 1 | 2013 | 3360 | 0.060 |
Why?
|
| Interleukin-18 | 1 | 2006 | 75 | 0.060 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2005 | 13 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 1287 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2011 | 1075 | 0.060 |
Why?
|
| Celecoxib | 1 | 2005 | 34 | 0.060 |
Why?
|
| Cardiac Tamponade | 1 | 2005 | 35 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2009 | 2602 | 0.060 |
Why?
|
| Trans-Activators | 1 | 2008 | 697 | 0.060 |
Why?
|
| Texas | 1 | 2013 | 3686 | 0.050 |
Why?
|
| Pericardial Effusion | 1 | 2005 | 78 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2006 | 1272 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 1129 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2009 | 2465 | 0.050 |
Why?
|
| Inflammation | 1 | 2012 | 1489 | 0.050 |
Why?
|
| DNA, Mitochondrial | 1 | 2006 | 233 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1722 | 0.050 |
Why?
|
| Adult | 5 | 2017 | 31282 | 0.050 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2008 | 478 | 0.050 |
Why?
|
| Prostatectomy | 3 | 2011 | 304 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3763 | 0.050 |
Why?
|
| Veterans | 1 | 2015 | 1763 | 0.050 |
Why?
|
| Age Factors | 1 | 2009 | 2825 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2005 | 362 | 0.050 |
Why?
|
| Hypogonadism | 1 | 2006 | 299 | 0.050 |
Why?
|
| Bortezomib | 2 | 2015 | 70 | 0.040 |
Why?
|
| Aromatase Inhibitors | 1 | 2002 | 81 | 0.040 |
Why?
|
| Androgen Antagonists | 1 | 2002 | 105 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2002 | 251 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 5196 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2012 | 4686 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 905 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1999 | 59 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2002 | 732 | 0.040 |
Why?
|
| Appetite | 2 | 2010 | 35 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2006 | 1586 | 0.030 |
Why?
|
| Interleukin-6 | 2 | 2012 | 412 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 294 | 0.030 |
Why?
|
| Connectome | 1 | 2018 | 111 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2018 | 3359 | 0.030 |
Why?
|
| Mutation | 1 | 2009 | 6099 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2013 | 17753 | 0.030 |
Why?
|
| Biopsy | 2 | 1999 | 1239 | 0.030 |
Why?
|
| Autografts | 1 | 2015 | 27 | 0.030 |
Why?
|
| Glomus Tumor | 1 | 1994 | 14 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 487 | 0.030 |
Why?
|
| Homeostasis | 1 | 2018 | 712 | 0.030 |
Why?
|
| Mitogens | 1 | 1993 | 30 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2015 | 250 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 227 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2012 | 3748 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 1993 | 210 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1993 | 236 | 0.020 |
Why?
|
| Castration | 1 | 2012 | 27 | 0.020 |
Why?
|
| Chromones | 1 | 2012 | 26 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2008 | 631 | 0.020 |
Why?
|
| Androstadienes | 1 | 2012 | 50 | 0.020 |
Why?
|
| Melanoma | 1 | 1999 | 931 | 0.020 |
Why?
|
| Morpholines | 1 | 2012 | 66 | 0.020 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2012 | 99 | 0.020 |
Why?
|
| Cell Division | 1 | 1993 | 718 | 0.020 |
Why?
|
| Hand Strength | 1 | 2012 | 59 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1993 | 975 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 1999 | 909 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2012 | 77 | 0.020 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2011 | 4 | 0.020 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2012 | 75 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2012 | 423 | 0.020 |
Why?
|
| Abdominal Neoplasms | 1 | 2011 | 31 | 0.020 |
Why?
|
| Fatigue | 1 | 2012 | 191 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2011 | 96 | 0.020 |
Why?
|
| Mechlorethamine | 1 | 1990 | 6 | 0.020 |
Why?
|
| Procarbazine | 1 | 1990 | 10 | 0.020 |
Why?
|
| Adiposity | 1 | 2012 | 209 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2012 | 3829 | 0.020 |
Why?
|
| Resistin | 1 | 2010 | 30 | 0.020 |
Why?
|
| Eczema | 1 | 1990 | 35 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 344 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 2114 | 0.020 |
Why?
|
| Prednisone | 1 | 1990 | 235 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 726 | 0.020 |
Why?
|
| Adiponectin | 1 | 2010 | 123 | 0.020 |
Why?
|
| Vincristine | 1 | 1990 | 187 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 450 | 0.020 |
Why?
|
| Phosphorylcholine | 1 | 2008 | 31 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2011 | 579 | 0.020 |
Why?
|
| Leptin | 1 | 2010 | 218 | 0.020 |
Why?
|
| Muscle Neoplasms | 1 | 2008 | 21 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 688 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 2082 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2011 | 892 | 0.020 |
Why?
|
| Cystectomy | 1 | 2008 | 143 | 0.020 |
Why?
|
| Risk Factors | 1 | 2002 | 11074 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 576 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 1363 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2008 | 257 | 0.020 |
Why?
|
| RNA Interference | 1 | 2008 | 491 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 732 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 1013 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 1378 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2008 | 440 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2008 | 765 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2006 | 44 | 0.010 |
Why?
|
| Ghrelin | 1 | 2006 | 58 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 2006 | 118 | 0.010 |
Why?
|
| Serum Albumin | 1 | 2006 | 101 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 2200 | 0.010 |
Why?
|
| Body Weight | 1 | 2010 | 987 | 0.010 |
Why?
|
| Peptide Hormones | 1 | 2006 | 68 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2012 | 1559 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1591 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2010 | 690 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2008 | 1483 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2006 | 324 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 639 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 1267 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 776 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2005 | 541 | 0.010 |
Why?
|
| Phenotype | 1 | 2012 | 4497 | 0.010 |
Why?
|
| Biomarkers | 1 | 2012 | 3385 | 0.010 |
Why?
|
| Apoptosis | 1 | 2008 | 1827 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2006 | 791 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 1673 | 0.010 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 1999 | 34 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2006 | 5063 | 0.010 |
Why?
|
| Skin | 1 | 1999 | 545 | 0.010 |
Why?
|
| Adolescent | 1 | 2010 | 20987 | 0.010 |
Why?
|